Hussman Strategic Advisors Inc. Has $1.91 Million Stake in PTC Therapeutics, Inc. $PTCT

Key Points

• Hussman Strategic Advisors cut its stake in PTC Therapeutics by 60% in Q4 to 25,200 shares valued at $1.91 million, even as other large investors (Vanguard, Wellington, State Street, UBS) largely increased their positions.
• PTC reported a significant quarterly miss—EPS of ($1.67) vs. ($0.21) expected and revenue of $164.7M vs. $281.5M expected, with revenue down 22.7% year‑over‑year—analysts are mixed but the consensus is a "Moderate Buy" with a $84.40 target.
• Insiders have been selling recently: executives (including the CEO and EVP) and others disposed of 126,492 shares worth $8.63 million over the last 90 days, leaving insiders with 5.5% ownership.

Hussman Strategic Advisors Inc. reduced its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 60.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,200 shares of the biopharmaceutical company's stock after selling 37,800 shares during the quarter. Hussman Strategic Advisors Inc.'s holdings in PTC Therapeutics were worth $1,914,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PTCT. Vanguard Group Inc. raised its position in PTC Therapeutics by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company's stock valued at $668,691,000 after purchasing an additional 514,204 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of PTC Therapeutics by 4.8% during the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company's stock worth $301,856,000 after purchasing an additional 224,481 shares during the last quarter. State Street Corp grew its holdings in shares of PTC Therapeutics by 22.1% during the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company's stock worth $146,347,000 after purchasing an additional 541,558 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of PTC Therapeutics during the third quarter worth $97,252,000. Finally, UBS Group AG grew its holdings in shares of PTC Therapeutics by 113.3% during the fourth quarter. UBS Group AG now owns 964,658 shares of the biopharmaceutical company's stock worth $73,275,000 after purchasing an additional 512,449 shares during the last quarter.

Analysts Set New Price Targets

PTCT has been the subject of a number of research analyst reports. Truist Financial raised PTC Therapeutics to a "strong-buy" rating in a report on Wednesday, March 25th. Jefferies Financial Group lowered shares of PTC Therapeutics from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $91.00 to $76.00 in a report on Monday, March 30th. Cantor Fitzgerald restated an "overweight" rating on shares of PTC Therapeutics in a research report on Friday, February 20th. Wall Street Zen downgraded shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. Finally, Royal Bank Of Canada reduced their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a "sector perform" rating on the stock in a research report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $84.40.

PTC Therapeutics Trading Up 0.1%

Shares of NASDAQ PTCT opened at $65.15 on Friday. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The firm's 50-day moving average is $67.97 and its 200-day moving average is $72.07. The firm has a market capitalization of $5.40 billion, a PE ratio of 8.42 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. During the same period last year, the firm earned ($0.85) earnings per share. The company's quarterly revenue was down 22.7% on a year-over-year basis. As a group, equities research analysts anticipate that PTC Therapeutics, Inc. will post -0.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Matthew B. Klein sold 7,371 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the transaction, the chief executive officer directly owned 387,082 shares in the company, valued at $26,848,007.52. This trade represents a 1.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Lee Scott Golden sold 10,000 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $63.38, for a total value of $633,800.00. Following the completion of the sale, the executive vice president owned 79,944 shares of the company's stock, valued at $5,066,850.72. This represents a 11.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 126,492 shares of company stock worth $8,634,621 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.